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Endometriosis is a complex, heterogeneous, chronic inflammatory condition impacting
∼176 million women worldwide. It is associated with chronic pelvic pain, infertility, and
fatigue, and has a substantial impact on health-related quality of life. Endometriosis is
defined by the growth of endometrial-like tissue outside the uterus, typically on the lining
of the pelvic cavity and ovaries (known as “lesions”). Macrophages are complex cells
at the center of this enigmatic condition; they are critical for the growth, development,
vascularization, and innervation of lesions as well as generation of pain symptoms.
In health, tissue-resident macrophages are seeded during early embryonic life are
vital for development and homeostasis of tissues. In the adult, under inflammatory
challenge, monocytes are recruited from the blood and differentiate into macrophages
in tissues where they fulfill functions, such as fighting infection and repairing wounds.
The interplay between tissue-resident and recruited macrophages is now at the forefront
of macrophage research due to their differential roles in inflammatory disorders. In
some cancers, tumor-associated macrophages (TAMs) are comprised of tissue-resident
macrophages and recruited inflammatory monocytes that differentiate into macrophages
within the tumor. These macrophages of different origins play differential roles in disease
progression. Herein, we review the complexities of macrophage dynamics in health and
disease and explore the paradigm that under disease-modified conditions, macrophages
that normally maintain homeostasis become modified such that they promote disease.
We also interrogate the evidence to support the existence of multiple phenotypic
populations and origins of macrophages in endometriosis and how this could be
exploited for therapy.
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BACKGROUND
Endometriosis is defined by the presence of endometrial-like tissue outside the uterus (“lesions”),
typically on the lining of the pelvic cavity (peritoneum) or on the ovaries. Endometriosis is a
heterogeneous disease, and lesions can be categorized into three sub-types: superficial peritoneal,
deep (infiltrating), and ovarian (“endometriomas”), where more than one sub-type can exist in the
same patient and superficial peritoneal endometriosis is the most common form of disease (1, 2).
It is associated with debilitating chronic pelvic pain, infertility, and fatigue. It is estimated to affect
6–10% of women of reproductive age (3), up to 50% of infertile women (4) and is prevalent in
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71–97% of women with chronic pelvic pain (5). Endometriosis-
associated symptoms can negatively impact mental, physical
and social well-being and quality of life (6). Poor pregnancy
outcomes are also associated with the disease, including
preterm labor, pre-eclampsia, ectopic pregnancy, miscarriage,
and intrauterine growth restriction (7). Endometriosis has a
significant socioeconomic impact, costing the UK an estimated
£8.5 billion pounds each year, with societal cost being mostly
attributed to loss of productivity (8, 9). Diagnosis from onset
of symptoms can take an average of 7–8 years. Generally, a
diagnosis of endometriosis is achieved by laparoscopic evaluation
of the pelvis, however imaging techniques such as transvaginal
sonography and magnetic resonance imaging may be utilized to
diagnose deep lesions and endometriomas (10–12).
Endometriosis lesions are characterized by the presence of
ectopic endometrial-like tissue containing glands and stroma,
however recent re-evaluation of disease definition suggests that
fibrosis and smooth muscle cells are more consistent features of
lesions (13). Endometriosis is classified as an estrogen-dependent
chronic inflammatory condition: symptoms are modulated by
ovarian hormones and lesions generate intense inflammation
within the pelvic cavity. Lesions also become vascularized
and are infiltrated by sensory nerve fibers (Figure 1). The
ectopic endometrial cells and local inflammatory environment
activate nerve fibers in lesions, establishing a dialogue with the
central nervous system and generating pain in the condition.
Lesions behave like the eutopic endometrium and exhibit
cyclical bleeding into the pelvic cavity in response to ovarian
hormones, and this acts to potentiate inflammation (14). Disease
classification (rAFS/rASRM) is currently based on lesion size,
location, extent of lesion infiltration into tissue and the presence
of adhesions. Classification ranges from stage I (“minimal”) to
stage IV (“severe”) (15).
Current treatments for endometriosis aim to alleviate
endometriosis-associated pain and/or to treat infertility
associated with the disease and include surgical and medical
management (2, 3). Ovarian suppression limits activity and
growth of lesions, leading to reduced pain symptoms. Common
methods of ovarian suppression include oral contraceptives
and gonadotrophin-releasing hormone (GnRH) agonists
(16) with add-back HRT. Whilst ovarian suppression may
alleviate pain symptoms, treatment is also contraceptive
and therefore inappropriate for women aiming to conceive.
Additionally, GnRH agonists are associated with side effects
such as memory loss, insomnia, and hot flushes in a recent study
of endometriosis patients with long term use (17). Treatments
can also include non-steroidal anti-inflammatory drugs such
as ibuprofen, however long-term pain management for women
with endometriosis often encompasses a combination of
treatments. As well as medical therapy, laparoscopic surgery to
remove lesions can provide symptom relief in some patients,
however up to 50% of women experience a relapse of symptoms
within 2 years after surgery (11). Current treatment options
lack significant clinically proven benefit and aim at alleviating
symptoms, rather than treating disease (18). Consequently, there
is a compelling clinical need for new non-hormonal treatments
that have fewer side effects and effectively treat endometriosis
FIGURE 1 | Endometriosis is a chronic inflammatory condition. Endometriosis
is characterized by the presence of endometrial-like tissue found outside the
uterus, most commonly in the peritoneal cavity. Endometriosis lesions are
heterogenous but usually contain endometrial stromal cells and epithelial
glands, immune cell infiltrates and are vascularized and innervated by nerves.
Created using Biorender.com.
over a life course, without the need for repeated surgeries or
suppression of fertility.
ETIOLOGY AND NATURAL HISTORY
It is widely accepted that endometriosis is a multifactorial
disease and the pathophysiology of endometriosis can certainly
be associated with a number of elements that clearly contribute
to disease. Evidence suggests that endometriosis has a heritable
component due to high familial incidence of the disease
(19–22). A meta-analysis of eight genome-wide association
studies (GWAS) elucidated six loci associated with endometriosis
(23). Genes implicated in disease included those involved in
the regulation of epithelial cells and hormone metabolism,
specifically genes involved in regulating hormone responses in
tissues (24, 25). These GWAS results are not surprising since
the symptoms of endometriosis are modulated by ovarian sex
steroids; early age at menarche is a risk factor for development
of endometriosis, suggesting increased exposure to estrogen
may incur increased risk of disease (26). Endometriosis lesions
aberrantly express a number of steroidogenic enzymes including
aromatase and 17β-hydroxysteriod dehydrogenase (17β-HSD),
this results in increased synthesis and decreased metabolism of
estrogen (27–29) such that local levels remain high. Estrogen
signaling modulates a large number of down-stream disease
processes within endometriosis lesions, which are reviewed in
Yilmaz and Bulun (30), Liang et al. (31), and Rizner (32).
Immune cell dysfunction is also intrinsically linked to the
pathophysiology of endometriosis. Alterations in immune cell
populations have been observed in the peritoneal fluid of women
with endometriosis; specifically, women with endometriosis have
more peritoneal macrophages (33), neutrophils and dendritic
cells (34). Function is also perturbed: NK cells have reduced
cytotoxicity (35, 36), and disease severity is positively correlated
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with NK cell killing capacity (37). Peritoneal macrophages
also exhibit impaired phagocytosis (38). Macrophages are the
most abundant immune cells present within endometriosis
lesions and are evidently central to the pathophysiology of
endometriosis. Whilst studies have highlighted clear functional
roles for macrophages in the disorder, little is known regarding
the origins and phenotypic heterogeneity of macrophages
in endometriosis.
Our understanding of endometriosis etiology remains limited.
It is being increasingly recognized that different sub-types of
endometriosis may arise from different origins, however evidence
for this is still limited (39, 40). A number of theories are
discussed below and we speculate on how the origin and role of
macrophages may differ in each scenario:
The most widely accepted theory was postulated in 1927
by John Sampson, who observed that during menstruation,
endometrial tissue can reflux back up the fallopian tubes
and into the pelvic cavity, a physiological process known as
“retrograde menstruation.” Although this process occurs in
∼90% of women, only in some does refluxed endometrial
tissue form endometriosis lesions (41) and the mechanisms
underpinning the attachment of endometrial tissue and lesion
development remain elusive. It could be predicted, and mouse
studies have demonstrated that macrophages originating from
the endometrium contribute to peritoneal endometriosis
lesions (42). These endometrial macrophages could be pivotal
in the establishment of lesions since it has previously been
demonstrated that macrophages trafficking to the endometrium
are most abundant during repair following endometrial
breakdown and shedding with a presumed role in repairing the
denuded functional layer of the endometrium (43). However,
evidence supporting this hypothesis is still absent. Another
theory based on the dissemination of cells from the uterus into
the peritoneal cavity suggests that neonatal retrograde reflux
of endometrial stem/progenitor cells could be responsible for
development of lesions. Visible vaginal bleeding is observed
in 3–5% of female neonates, whereas occult bleeding may
occur at a frequency of between 25 and 60% (44). Bleeding
in the immediate postnatal period is similar to menstrual
bleeding as it occurs in response to hormone withdrawal
from in utero progesterone exposure. This theory suggests
that stem/progenitor cells could implant into the peritoneal
wall where they may remain dormant until adolescence, when
elevated estrogen levels may then promote the proliferation and
growth of seeded endometrial cells. Whilst, this theory represents
a plausible mechanism of lesion formation, current evidence
is lacking and proof that endometrial stem/progenitor cells are
present in the peritoneal tissue of pre-pubescent girls is absent.
The coelomic metaplasia theory suggests that endometriosis
lesions arise as the result of metaplastic differentiation of the
coelomic epithelium into endometrial cells and is supported
by evidence suggesting endometriosis lesions can be found in
women without a uterus (45). The formation of endometriosis
lesions at sites distant from the peritoneal cavity (46, 47), as
well as identification in men on rare occasions (48) supports
the theory. Upon development of lesions at the onset on
adolescence (neonatal stem cell theory) or following metaplasia
it would be expected that monocytes are recruited to the site
of the lesion and/or that peritoneal macrophages may traffic
into the developing lesion and activate repair processes that
facilitate establishment of new endometrial-like explants.
Notably, stem cells and macrophages are known to have a
reciprocal relationship whereby stem cells can contribute to
macrophage activation and phenotype during regenerative
processes and macrophages can dictate accumulation
of progenitor/stem cell-like cells (49). In endometriosis,
mesenchymal stem-like cells promote macrophages to adopt
a pro-repair phenotype (50) but further studies regarding
the relationship between stem cells and macrophages in
endometriosis are currently limited. Müllerianosis (müllerian
rests; normal endometrial, endosalpingeal, and endocervical
tissue) predicts that developmentally displaced tissue are
incorporated into normal organs during organogenesis (51).
Occurrence of deep infiltrating endometriosis particularly
lends itself to this theory, where endometrial tissue is found
deep within the organ structure. Speculation may infer a
role for tissue-resident macrophages in lesions resulting from
developmentally displaced endometrial-like tissue. Upon
activation of a “dormant” lesion laid down during organogenesis
the tissue-resident macrophages may change phenotype and
proliferate such that they promote inflammation, growth, and
invasion of the lesion. Inflammation arising upon activation of
a dormant lesion may also lead to the recruitment of monocytes
that differentiate into macrophages such that endometriosis
lesion-resident macrophages are constituted by tissue-resident
and monocyte-derived macrophages similar to what occurs in
tumors (52). Any differences existing in macrophage origin,
phenotype and function across the different subtypes of
endometriosis lesions remain unknown.
THE MACROPHAGE: A COMPLEX CELL AT
THE CENTER OF AN ENIGMATIC
CONDITION
Inflammation and immune cell dysfunction are central to
the pathophysiology of endometriosis. Whilst, a number
of leukocytes exhibit altered numbers and function in
endometriosis, it is evident that macrophages play an
unrivaled role in disease pathogenesis. We and others have
demonstrated that macrophages are critical for licensing lesion
growth, promoting vascularization and innervation as well as
contributing to pain in the disorder (53–55). Lessons from
diverse tissues also place macrophages at the center of disease
states such as liver injury (56), multiple sclerosis (57), and cancer
(52). Tissue context ultimately dictates the role that macrophages
play in disease but a recurring theme indicates that the ontogeny
of the macrophages in diseased tissues determines how they
respond and contribute to pathogenesis. Below, we review
the available literature on macrophage ontogeny, phenotype
and function in health and then focus on their role during
inflammation and disease states. Ultimately, we discuss the role
that macrophages play in endometriosis in light of what can be
learnt from other disease states.
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Macrophages Have Different Origins and
Diverse Phenotypes
Macrophage Ontogeny
Macrophages are mononuclear phagocytes that play critical
roles in immunity (phagocytizing pathogens, apoptotic cells and
debris, antigen presentation, and modulation of other leukocyte
populations). They are present in all tissues of the body (58, 59)
and play diverse tissue specific roles in maintaining homeostasis.
Much of our knowledge regarding macrophage ontogeny is
derived from studies conducted in mice. Macrophages are
derived from three key populations; the yolk sac of the embryo,
the fetal liver and postnatally, hematopoiesis in the bone marrow
(Figure 2). The earliest macrophages arise from erythro-myeloid
progenitors (EMPs) produced during primitive hematopoiesis in
the extra-embryonic yolk sac at embryonic day (E) 7.5 and 8.25.
After blood circulation is established, EMP derived macrophages
seed fetal tissue. Excluding microglia, these macrophages are
partially or fully replaced by monocytes originating from the fetal
liver, which differentiate into macrophages in tissues. Fetal liver
monocyte-derived macrophages can persist into adulthood and
form the tissue residentmacrophage population, undergoing self-
renewal, for example in the peritoneum, spleen, lung, skin, and
liver. In other organs, tissue macrophages derived from fetal liver
monocytes are gradually replaced by recruited monocytes from
the bone marrow. This process occurs in tissues such as the gut
and dermis (60–64).
In humans, peripheral blood monocytes form two main
populations; CD14hi CD16lo and CD14lo CD16hi, although
FIGURE 2 | Macrophages are mononuclear phagocytes. Tissue macrophages
are seeded during fetal life from the fetal liver and yolk sack and undergo
self-renewal. In adults, monocyte precursors extravasate from the bone
marrow into the circulation, where they can then infiltrate into tissues and
differentiate into macrophages. In tissues, macrophages modulate their
phenotype dependent on local cytokines and growth factors to specific tissue
or disease-associated phenotypes.
an intermediate population can be identified. The CD14hi
CD16lo (classical) subset is the most abundant in the blood.
Under inflammatory conditions, classical monocytes extravasate
into tissues, differentiate into macrophages or dendritic cells
(65) and fulfill functions such as clearance of apoptotic
bodies, stimulating angiogenesis and restoring integrity of
tissues (66). CD14lo CD16hi (“non-classical”) monocytes also
exhibit extravasation into tissues during inflammation, but
they infiltrate tissues later in the inflammatory process and
exhibit a bias toward differentiating into “wound-healing”
macrophages (67). A key role of the non-classical monocyte
population is to patrol the blood vessels along the endothelial
cell layer, providing immunosurveillance of vasculature and
the surrounding tissues (68). Classical monocytes also patrol
tissues and play a homeostatic role in steady state conditions,
without differentiating into macrophages (69). Classical and
non-classical monocytes in humans are analogous to Ly6Chi
classical and Ly6Clo non-classical monocytes in mice and
exhibit significant homology at transcriptional analysis (70, 71).
In mice, classical monocytes can be classified as Ly6Chi
CX3CR1lo CD43loCCR2hi, and non-classical monocytes as
Ly6Clo CX3CR1hi CD43hiCCR2lo, with all monocyte populations
being CD11bhi F4/80int (65).
Macrophage Phenotype
Macrophages respond to their local microenvironment and
change both their transcriptome and phenotype in response
to local signals (72). Historically, macrophages have been
divided into either “M1” classically or “M2” alternatively
activated cells. Classically activated macrophages are associated
with inflammation, and express pro-inflammatory markers.
Alternatively activated macrophages are associated with
homeostasis, wound healing and immunomodulation (73).
These extreme polarization states only really exist in vitro,
where studies commonly use stimulation with granulocyte-
macrophage colony-stimulating factor (GM-CSF) and the
cytokine IFN-γ (Interferon γ) to generate M1 macrophages,
and stimulation with macrophage colony-stimulating factor
(M-CSF) and the cytokines interleukin-4 (IL-4) and interleukin-
10 (IL-10) to generate M2 activated macrophages (74). Whilst,
this classification system is a useful tool for investigating
macrophages at extremes of activation, it is now appreciated that
in vivo macrophages exhibit a broad spectrum of phenotypes
that are tissue and disease specific, and the M1/M2 system
cannot represent the diverse nature and complexities of
macrophage phenotype (75, 76). Transcriptional analysis
of mouse macrophage populations from different tissues
demonstrates minimal overlap in mRNA expression, reflecting a
divergence in gene expression patterns (77). This heterogeneity
reflects the ability of macrophages to modulate their gene
expression in response to local tissue signals, becoming
specialized to their tissue niche, be that in a healthy or diseased
state. In disease, macrophages may modulate their phenotype
dependent on disease stage or severity, and the mechanisms
behind this are crucial for understanding their exact role in
pathogenesis. Thus, defining macrophage phenotypes in disease
states, with the potential of modulating macrophage phenotype
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or specifically targeting disease specific macrophages for clinical
benefit is a key focus for research (72, 78–80).
Endometrial Macrophages
The endometrium is a unique and highly dynamic tissue
that undergoes cyclic proliferation, differentiation, shedding
(menstruation), and repair in response to ovarian-derived
estrogen and progesterone during the menstrual cycle. In
the normal cycling endometrium, an influx of macrophages
occurs during the secretory and menstrual phases, along with
a concomitant increase in macrophage-derived cytokines and
proteases (81). Evidence from a mouse model of endometrial
breakdown and repair identified an influx of classical monocytes
which differentiated into macrophages in the endometrium
during the repair phase of the menstrual cycle (43). Monocyte
extravasation from blood vessels into the endometrium is
regulated by CCL2 (82, 83) and CX3C chemokine receptor
1 (CX3CR1) (84). The influx of macrophages into the
endometrium is in line with the numerous roles they are
presumed to play in modulating endometrial differentiation,
breakdown, and repair. During the proliferative phase,
macrophages have been postulated to play a role in regeneration
and proliferation of the functional layer of the endometrium
and express activation and adhesion markers CD54, CD69, and
CD71 (85). Macrophages are also implicated in regulating gland
remodeling (86) and angiogenesis during the secretory phase
via production of vascular endothelial growth factor (VEGF)
(87). At menstruation macrophages play a role in initiation of
endometrial shedding by secreting matrix metalloproteinases
(MMPs) (88). Specifically, secretion of MMP-12, MMP-9, and
MMP-14 are required for the breakdown of the functional layer
of the endometrium during menstruation (89–91).
In response to estrogen, macrophages increase their
proliferative capacity and undergo activation to adopt a
phenotype which represents a more “wound healing-like”
population (92). Thus, estrogen signaling can accelerate
the wound healing process and this is in part regulated by
increasing the production of macrophage-derived proteases,
MMPs, fibroblast growth factor, VEGF and cytokines such as
resistin like alpha (RELMα) (92–94). Endometrial macrophages
do not express the progesterone receptor (95), however
macrophage gene expression is significantly altered in response
to progesterone (96) suggesting an indirect method of regulation.
Interestingly, exposure to cortisol was demonstrated to increase
expression of angiogenic genes such as CXCL2, CXCL8, and
VEGFC in macrophages in vitro, suggesting that local cortisol
levels could be important for regulating angiogenesis within the
remodeling endometrium (97). Taken together this evidence
indicates that macrophages are key players in augmenting
dynamic remodeling and repair in the endometrium and this
is regulated by exposure to local cytokines, growth factors
and hormones that modulate their phenotype, function,
and recruitment throughout the menstrual cycle. However,
compared to other tissue macrophages, the phenotype and
function of endometrial macrophages and the mechanisms
governing their recruitment and activation are significantly
less well-characterized.
Peritoneal Macrophages
Mouse
Peritoneal cavity macrophages are one of the most studied
macrophage populations in mice, largely due to their ease of
isolation. Two subsets of peritoneal macrophages are recognized
in mice based on differential expression of F4/80 and MHC II.
The tissue resident, so called “large” (due to their larger size)
peritoneal macrophages (LpM) are F4/80hi, MHC IIlo, and the
monocyte-derived “small” peritoneal macrophages (SpM) are
F4/80lo MHC IIhi (98). LpM are the most abundant macrophage
population in the peritoneal cavity at steady state and form
the tissue resident population, they are phagocytic and perform
immunosurveillance and homeostatic roles in the peritoneal
cavity (98) as well as mediating recruitment and maintenance
of B1 B cells. They are also linked to regulation of intestinal
immunity (99). LpM self-renew and the proliferative capacity
of LpM is regulated by GATA-binding factor 6 (Gata6), a
transcription factor uniquely expressed by LpM in the peritoneal
cavity, which also regulates macrophage phenotype (100). In
mice, the LpM population consists primarily of embryonic-
derived cells, however monocyte-derived macrophages do
replace embryonic-derived LpM over time, a process that is
highly sex and age dependent, and slower in females. Over
time, Ly6Chi monocytes enter the peritoneal cavity in a CCR2-
dependent manner and differentiate transiently into SpM, prior
to transitioning into tissue resident LpM (101). Thus, the LpM
constitute both embryonic and monocyte-derived cells and the
two populations have been shown to be transcriptionally distinct
from each other (101). SpM are implicated in the inflammatory
response in the peritoneal cavity, however their role in the steady
state peritoneal cavity remains unclear (102).
Human
In humans, macrophages constitute 50% of peritoneal cavity
leukocytes (103). Tissue resident peritoneal macrophages have
been defined by high expression of complement receptor of
the immunoglobulin superfamily (CRIg) and low expression of
CCR2. These cells are highly phagocytic and more numerous
in steady state, also displaying similar transcriptional profiles
to the mouse LpM population (104). Human monocyte-derived
macrophages in the peritoneal cavity, analogous to F4/80lo MHC
IIhi SpM in the mouse, have been defined as CRIglo, CCR2hi. This
CRIglo, CCR2hi population in humans has a reduced phagocytic
capacity and is lower in number compared to CRIghi CCR2lo
tissue macrophages, consistent with characteristics of SpM. It
must be noted however that in humans, Gata6 was found to
be more highly up-regulated in the pro-inflammatory CRIglo
CCR2hi population (104), highlighting that key differences
between human and mouse peritoneal macrophages exist, and
further research is critically required to clarify these differences.
Peritoneal Macrophage Dynamics During
Inflammation
Under inflammatory conditions, LpM respond to stimuli in a
phenomenon known as the macrophage disappearance reaction
(MDR) (105): in mice the LpM compartment undergoes a
dramatic reduction in numbers largely by migration to the
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omentum, mediated by retinoic acid and Gata6 (106). The
degree of loss in the LpM population is highly dependent on
the dose of inflammatory stimuli and has been studied in a
number of inflammatory models, such as lipopolysaccharide
(LPS), zymosan or thioglycollate induced peritonitis (107–109).
LpM that persist during inflammation have been hypothesized
to play a regulatory role in the peritoneal cavity by secretion
of IL-10, an anti-inflammatory cytokine which has also been
shown to regulate inflammatory SpM number (109). LpM
also play a key role in clearance of apoptotic cells during
inflammation (108), and exhibit high expression of T-cell
immunoglobulin and mucin domain containing 4 (Tim4) which
recognizes phosphatidyl-serine on apoptotic cell bodies (110).
Upon resolution of inflammation, the depleted LpM population
increases its proliferative capacity through a colony stimulating
factor 1 receptor (Csf-1r) mediated mechanism to restore LpM
number (107). Interestingly, LpM have been shown to infiltrate
the liver by a non-vascular route in response to the damage-
associated molecular pattern molecule (DAMP) ATP, where they
play a key role in regeneration and tissue repair in the liver
after sterile injury, modulating their phenotype in response
to local tissue microenvironmental cues (111). This migration
implies that LpM have the ability to execute wound repair
and tissue regeneration in visceral organs. Furthermore, with a
reduction of LpM numbers a concurrent increase in SpM and
inflammatory Ly6Chi monocytes is observed in a number of
mouse models of peritoneal inflammation (105). SpM exhibit
a pro-inflammatory response when challenged with LPS in
vitro, producing high levels of chemokine (C-C motif) ligand
5 (Ccl5), chemokine (C-C motif) ligand 3 (Ccl3), and tumor
necrosis factor-α (Tnf-α), as opposed to LpM which produce
G-CSF and GM-CSF under LPS stimuli (102). In an in vivo
model of peritonitis, SpM also produce high amounts of pro-
inflammatory cytokines including Tnf-α, interleukin-1β (Il-1β),
and Ifn-γ (112), and are critical for clearance of infection in the
peritoneal cavity after bacterial challenge in the mouse (113).
The ability of SpM to respond to inflammatory stimuli by
producing pro-inflammatory cytokines enables rapid response to
immunological challenge in the peritoneal cavity. At resolution
of inflammation, SpM have been shown to undergo apoptosis
(108) but can also migrate to local draining lymph nodes (114).
However, SpM have also been shown to persist in the cavity
and can eventually differentiate into F4/80hi MHC IIlo cells
(115), suggesting that inflammation has the potential to alter
the complement of peritoneal cavity macrophage populations,
even after homeostasis has been restored. The multiple fates
of SpM reflect the heterogeneity in this cell compartment, but
the roles of SpM sub-populations in inflammation are still
largely undefined. In summary, under steady-state/homeostatic
conditions LpM exhibit an immune-surveillance and immune-
regulatory role and act to remove apoptotic and senescent
cells. The roles of SpM are less well-defined but the markers
they express suggests roles in antigen presentation and T cell
activation. Inflammatory challenge with thioglycolate, zymosan
or LPS (lipopolysaccharide) causes loss of LpM and expansion
of SpM via monocyte recruitment and differentiation. New SpM
are pro-inflammatory, expressing high levels of Tnfα, Il-1β,
and Ifnγ and are better able to engulf microbes compared to
homeostatic SpM. Of note, type-2 inflammation characterized
by elevated levels of IL-4 does not induce MDR and instead
F4/80hi LpM accumulate in the peritoneal cavity and exhibit a
pro-repair phenotype (116). Thus, it seems that under different
inflammatory challenge LpM are biased to exhibit a pro-repair
phenotype whilst SpM adopt a pro-inflammatory phenotype.
Mechanistic studies on peritoneal macrophages in humans are
challenging and therefore knowledge of this physiological process
in humans is minimal.
Macrophages Can Promote Disease
The unique and diverse roles that macrophages play in
the maintenance of healthy tissues is mirrored by their
pivotal roles in development, maintenance, and progression
of a number of diseases (72). Peritoneal cavity macrophage
perturbations and functional dysregulation are linked to
a number of adverse clinical outcomes. For example, an
increase in peritoneal macrophages was associated with negative
outcomes in patients with peritonitis (109), and dysregulation
of peritoneal macrophages has been linked to acute pancreatitis,
where peritoneal macrophages produce increased levels of
pro-inflammatory cytokines that exacerbate disease (115).
Conversely, macrophages have been shown to be protective
against the formation of adhesions, a common complication
after abdominal surgery (117) and indicating that macrophage
dysfunction could contribute to adhesion formation. Thus,
macrophages are intrinsically linked to disease in the peritoneal
cavity in humans.
Although endometriosis is a benign condition a number
of parallels can be drawn between the condition and cancer
(118). Macrophages are unambiguously at the center of the
pathophysiology of both diseases. Macrophage infiltration in
tumors is a predictor of poor clinical outcomes in malignancy
(119, 120), attributed to the fact that macrophages promote
initiation, progression, and metastasis in most cancers (75). In
the last decade, a major focus has been to define the populations
that constitute tumor-associated macrophages (TAMs). In a
mouse model of breast cancer, Ly6Chi inflammatory monocytes
are recruited to metastatic sites via a CCR2/CCL2 mediated
mechanism to form TAMs. Inhibition of CCL2/CCR2 signaling
with an anti-CCL2 antibody inhibited monocyte recruitment
thereby inhibiting metastasis and prolonging survival of the
mice (121). Similarly, mouse models of Lewis lung carcinoma
demonstrated that TAMs were derived from CCR2 driven
recruitment of Ly6Chi monocytes and blockage of CCL2
decreased tumor growth (122, 123). Furthermore, tissue
resident macrophages have also been implicated in cancer
pathophysiology and can contribute to the TAM population. For
example, in a mouse model of pancreatic ductal adenocarcinoma,
Zhu et al. demonstrated using a parabiosis model that TAMs
were derived from both embryonically derived tissue resident
macrophages as well as from circulating Ly6Chi monocytes.
During tumor development embryonically derived macrophages
expanded via in situ proliferation and had a pro-fibrotic role
in tumors. Using a Csf-1r neutralizing antibody and clodronate
liposome treatment to deplete tissue resident macrophages a
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reduction in tumor size and increased survival of mice was
observed. Monocyte-derived macrophages however played a key
role in antigen presentation. Use of CCR2 knockout mice or
a CCR2 inhibitor to prevent recruitment of Ly6Chi monocytes
did not affect tumor growth (52). This study highlights the
importance of defining the ontogeny of TAMs in order to
decipher which populations are fundamentally required for
tumor growth, with the aim of improving clinical outcomes.
Whilst TAMs may have multiple origins, it has been
demonstrated that the tumor microenvironment can modulate
macrophage phenotype to promote malignancy, indicating that
origin does not wholly define function when macrophages
are exposed to cytokines and growth factors locally in the
tumor. A number of different macrophage populations within
tumors have been described which play differential roles and
have different phenotypes. For example, populations of invasive,
perivascular, metastasis associated, angiogenic (Tie2+), and
immunosuppressivemacrophages which secrete high levels of IL-
10 have been described (75). Detailed profiling of hepatocellular
carcinoma biopsies demonstrated the presence of various
macrophage sub-types in tumors that had both pro and anti-
tumoral properties (124).
The Role of Macrophages in Endometriosis
Macrophage Ontogeny in Endometriosis
Whilst, a role for macrophages in endometriosis pathophysiology
is established (and discussed below), the ontogeny of
endometriosis-associatedmacrophages is still poorly understood.
Greaves et al. demonstrated in a syngeneic mouse model of
endometriosis that lesion resident macrophages are derived
from both the (donor) endometrium and (recipient) infiltrating
macrophage populations (42) (Figure 3). These infiltrating
macrophage populations are likely to constitute peritoneal
or recruited monocyte-derived macrophages, however the
exact origins of these populations is currently unknown.
Although, peritoneal macrophages contribute to inflammation
in endometriosis, it remains unknown whether they infiltrate
endometriosis lesions and thus the role these cells play within
the ectopic tissue is not known. Using bone marrow chimeras
Sekiguchi et al. demonstrated that CD11b+ cells from the
bone marrow infiltrate and accumulate in endometriosis
lesions in a mouse model (125). These cells could represent a
monocyte/macrophage population, although CD11b+ cells could
also constitute neutrophils, eosinophils and or certain subsets of
dendritic cells (126). Capobianco et al. demonstrated that bone
marrow derived Tie2+ cells infiltrated endometriosis lesions in
a mouse model, again demonstrating that bone marrow derived
cells that ultimately express macrophage markers within lesions
could be recruited from blood vessels (127).
Macrophage Phenotype and Function in
Endometriosis
Endometrial macrophages exhibit differential properties
in endometriosis. Reflecting on the theory of retrograde
menstruation and studies in mice identifying endometrial
macrophages in lesions, the presence of macrophages in refluxed
endometrial tissue in women has the potential to augment disease
development in the peritoneal cavity. A number of studies have
demonstrated perturbations in macrophage populations in
the eutopic endometrium of endometriosis patients. Women
with endometriosis have more endometrial macrophages that
express lower levels of the “wound-healing” marker CD163
compared to women without disease, however the exact
mechanisms behind these alterations are unknown (128, 129).
Analogous to this, increased levels of CCL2 can be observed in
the endometrium of women with disease which corresponds
FIGURE 3 | Endometriosis lesions are infiltrated by blood vessels, nerves, and macrophages. Lesion resident macrophages are derived from macrophages originating
from the endometrium and recruited macrophages. Macrophages interact with blood vessels and nerves to stimulate their growth. Signaling also occurs between
macrophages and stromal cells, which increases their clonal expansion and invasive properties. Created using Biorender.com.
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to disease severity, suggesting increased influx of monocytes
in disease that can then differentiate into macrophages (130).
Increased matrix metalloproteinase-9 (MMP-9) co-localized
with CD68+ macrophages in the endometrium of women with
endometriosis is indicative of an increase in the number of
macrophages implicated in tissue remodeling. This may enhance
the ability of ectopic endometrial tissue deposits to implant
in the peritoneal cavity (131). Whilst evidence of macrophage
perturbations in the eutopic endometrium of women with
endometriosis exists, the role of endometrial macrophages in
endometriosis has not been defined as functional studies in this
area are lacking.
Women with endometriosis evidently have an increased
number of peritoneal macrophages that exhibit a dysfunctional
phenotype. Peritoneal macrophages collected from women with
endometriosis have reduced phagocytic capacity due to low
levels and activity of matrix metalloproteinase 9, which is
required for extracellular matrix degradation and is regulated
by prostaglandin E2 (PGE2) (38). In a co-culture system, in
the presence of endometrial stromal cells isolated from ectopic
endometrial tissues, monocyte-derived macrophages secreted
IL-10 and TGF-β, which in turn suppressed cytotoxicity and
viability of NK cells (132), suggesting that macrophages are
immunosuppressive in the presence of ectopic endometrial
stromal cells and can act to suppress NK cells in the peritoneal
cavity. Whilst, a few studies have investigated peritoneal
macrophages in women with endometriosis the cells have been
evaluated as a global population and there are no studies
pertaining to the constitution and function of the individual
CRIghi and CRIglo populations of these cells: the abundance and
behavior of CRIghi population in women with endometriosis
is not known, although inflammation and survival of refluxed
endometrial tissue suggests that in endometriosis this tissue
resident population could act to create a permissive and
mitogenic environment for the formation of lesions. Analogous
to this, a study by Beste et al. demonstrated enhanced expression
of both pro- and anti-inflammatory cytokines by macrophages
collected from the peritoneal fluid of women with endometriosis,
this could reflect the mixed population of cells present (133).
The increased number of peritoneal macrophages in women with
endometriosis suggests that in the condition the “macrophage
disappearance reaction” (MDR) does not occur. Indeed, it
has been previously demonstrated that in type-2 inflammation
characterized by high level of IL-4 the MDR does not happen
and peritoneal macrophages accumulate as a result of in situ
proliferation (116). IL-4 concentrations are elevated in the
peritoneal fluid of women with endometriosis (134) suggesting
that this could be a mechanism for macrophage accumulation.
However, because the abundance of the different populations has
not been characterized this hypothesis remains to be proven.
Mouse models of endometriosis provide conflicting evidence of
peritoneal macrophage dynamics: Yuan et al. demonstrated that
in a model that injects syngeneic, estradiol primed, endometrial
fragments into intact mice, those with endometriosis exhibited
significantly lower numbers of LpM and more abundant
SpM compared to control mice, consistent with the MDR.
These perturbations in peritoneal macrophage populations were
evident from 0.25 to 42 days post tissue injection (135). However,
in a model injecting “menses-like” endometrial tissue into
ovariectomized recipients supplemented with estradiol valerate,
loss of LpM was not observed, and mice with endometriosis
had more abundant LpM compared to naïve and sham animals
[although the increase was not statistically significant (54)]. The
second study seems to more closely recapitulate macrophage
dynamics in women with endometriosis, although evidence is
very limited. The differences observed in these two studies could
be a result of several differences in experimental design including
the nature of the donor endometrium injected into the peritoneal
cavity as well as manipulations performed on the recipient mice.
Yuan et al. also demonstrated that in mice with endometriosis
LpM exhibited a “pro-inflammatory” activation state and SpM
were more “pro-repair” in nature (135). This interpretation
was based on expression of NOS2 (inflammatory) and CD206
(repair) and is contradictory to others studies reporting the pro-
inflammatory status of SpM and pro-repair status of LpM in
response to different inflammatory stimuli.
Although, it has been demonstrated that monocytes are
recruited to lesions from the bone marrow, little evidence exists
to characterize their role and dynamics once they infiltrate
ectopic tissue. Johan et al. examined infiltrating macrophage
phenotype over time in endometriosis lesions in a heterologous
mouse model and found that macrophage phenotype was
progressively altered over time. Macrophages initially expressed
pro-inflammatory markers iNOS and major histocompatibility
complex II (MHC II), however at 7 and 14 days post
lesion induction a higher proportion of macrophages expressed
arginase 1 and CD204 (scavenger receptor A), which are more
associated with a tissue remodeling phenotype (136). This
study therefore demonstrates that macrophage phenotype in
endometriosis lesions is dynamic and progressively changes as
lesions develop in the peritoneal cavity. However, as with other
studies, the limited number of markers assessed makes it difficult
to truly re-capitulate the complex phenotype of macrophages in
the tissue.
Endometriosis lesions from women are highly infiltrated
by CD68+ macrophages that are present within the stroma
of the tissue and can also be found in close proximity to
glands (42, 53). Studies in women have strongly implied a
role for macrophages in endometriosis, but the mechanistic
studies performed in experimental models have significantly
improved our understanding of the role of macrophages in
the condition. Studies to date have largely focused on defining
the role of macrophages in syngeneic mouse models using
various cell depletion approaches. A commonly utilized depletion
method uses liposomes encapsulating bisphosphonates. These
liposomes are taken up by phagocytic cells, which degrade the
liposomes, releasing bisphosphonate and causing subsequent
cell death. This method therefore selectively depletes phagocytic
cells and is non-toxic to non-phagocytic cells, and has been
commonly used to deplete phagocytic macrophage populations
(137). In a syngeneic mouse model of disease, Bacci et al. used
clodronate liposomes and a monoclonal anti-F4/80 antibody to
deplete/inhibit peritoneal macrophage function in mice with
induced endometriosis and demonstrated that both treatments
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caused a reduction in growth and blood vessel formation in
lesions (53). Adoptive transfer of in vitro generated “pro-
inflammatory” (stimulated with IFN-γ), “anti-inflammatory”
(stimulated with macrophage-colony-stimulating factor and IL-
10), or “non-polarized” (stimulated with macrophage-colony-
stimulating factor) macrophages lead to differential effects
on lesion development. “Non-polarized” macrophages had no
effect on lesion number or weight, however adoptive transfer
of pro-inflammatory macrophages reduced lesion weight.
Conversely, adoptive transfer of anti-inflammatory macrophages
caused an increase in lesion weight. The authors noted that
lesion architecture was also disrupted in mice which had
received adoptive transfer of pro-inflammatory macrophages
(53). Together, this data suggests that anti-inflammatory/pro-
repair macrophages may be important for the growth and
development of lesions and pro-inflammatory macrophages have
an antagonistic effect, clearing ectopic endometrial tissue and
disrupting lesion architecture. Whilst this data provides an
important insight into the roles of macrophage phenotypes in
endometriosis, the use of the M1/M2 paradigm is limited and the
exact phenotype and phenotypic heterogeneity of macrophages
in endometriosis and their role in disease is currently unknown.
Capobianco et al. identified Tie-2 expressing macrophages that
infiltrated mouse and human lesions. Depletion of Tie-2+
macrophages was achieved using a bone marrow chimera from
mice expressing a suicide gene (herpes simplex virus type 1
thymidine kinase) expressed under control of the Tie2 promoter
into wild-type mice. After treatment with ganciclovir (an anti-
viral drug), bone-marrow derived Tie2+ cells were selectively
depleted and growth of endometriosis lesions was inhibited,
with loss of neovascularization and glandular organization in
the resultant lesions (127). Sekiguchi et al. demonstrated that
VEGFR1 knockout mice had smaller and less vascularized lesions
thanWT in amouse model where sections of uterus were sutured
onto the peritoneal wall. Using bone marrow chimeras they
demonstrated that VEGFR1+ cells in lesions were bone marrow
derived CD11b+ macrophages (125). WT endometriosis mice
were also treated with clophosome N which depleted phagocytic
cells in the peritoneal cavity at the time of endometriosis
induction, and demonstrated that growth and angiogenesis in
lesions was reduced (125). A similar study using liposomal
bisphosphonate to deplete phagocytic peritoneal populations also
demonstrated reduced growth of endometriosis lesions in a rat
model (138). Thus, it seems clear that in experimental models
of endometriosis, depletion of peritoneal phagocytic macrophage
populations inhibits growth and angiogenesis of induced lesions.
Endometriosis lesions exhibit cyclical bleeding in response to
ovarian steroids in the same context as the eutopic endometrium,
thus lesions can perceived as wounds undergoing recurrent
tissue injury and repair (40). The process in lesions has
been described to involve epithelial-mesenchymal transition,
fibroblast-myofibroblast transdifferentiation, smooth muscle cell
metaplasia and fibrosis (139). Macrophages are critical for
successful repair and regeneration in tissues; they stimulate local
fibroblasts to differentiate into myofibroblasts to facilitate wound
contraction (140). During wound repair the proliferation and
expansion of local stromal cells is also regulated by macrophages
and if the injury is severe, macrophages may activate additional
stem cell and local progenitor cell populations that participate
in repair (49). In line with these established roles in tissue
injury and repair in vitro studies have aimed at assessing the
interaction between endometrial stromal cells and macrophages
in endometriosis. In a co-culture system, culture of endometrial
stromal cells with autologous macrophages isolated from women
with endometriosis increased the invasive and clonogenic ability
of stromal cells (141). Co-culture with ectopic endometrial
stromal cells was also shown to decrease the phagocytic capacity
of macrophages and increased the survival and proliferation of
stromal cells compared to eutopic endometrial stromal cells in
a study by Mei et al. (142). A similar effect was also reported
by Shao et al. (143). Reciprocal signaling therefore appears to
be occurring between ectopic endometrial stromal cells and
macrophages, which could contribute to their survival and the
formation of endometriosis lesions in the peritoneal cavity,
however the precise mechanisms are yet to be elucidated and
the specific macrophage populations involved are unknown.
Stromal cells derived from ovarian endometrioma were found to
express markers of mesenchymal stromal cells (MSCs), formed
colony forming units and exhibited multipotency suggesting
characteristics of mesenchymal stem-like cells. The MSCs
from endometriomas promoted differentiation of monocytes to
spindle shaped pro-repair/immunosuppressive macrophages in
vitro (50). The results suggest that MSC influence macrophages
such that they exhibit an immunosuppressive phenotype and
support lesion growth. The coordination of monocytes and
macrophage activation states during inflammation and repair
is tightly and temporally controlled. If disturbances occur at
any point in the process this can lead to aberrant repair
and the formation of pathological fibrosis (49). For example,
persistent activation and sustained recruitment of pro-repair
macrophages may contribute to pathological fibrosis (144). Since
endometriosis lesions are undergoing consistent and repeated
episodes of injury and repair and lesions exhibit fibrotic content,
the events required for efficient, scarless repair may be disturbed.
Depletion studies have demonstrated that macrophage depletion
significantly reduces the fibrosis in lesions. Moreover, adoptive
transfer of macrophages polarized in vitro to exhibit an M2a
phenotype (activated with IL-4) increased the fibrotic content
of lesions (139). Thus, it seems that unlike the physiological
wound repair process, endometriosis lesions cannot enter the
resolution phase of inflammation and repair and the local
inflammatory environment causes persistent activation of pro-
repair macrophages that contribute to fibrosis.
A role for macrophages in neurogenesis in endometriosis
lesions has been established in the literature, suggesting a role
in the generation of endometriosis-associated pain. Indeed,
nerve infiltration in lesions is positively correlated with higher
reported pain scores in women (145). Cholinergic, adrenergic,
sensory Aδ and C nerve fibers have been identified in
lesions (146, 147), and macrophages are densely populated
in areas of high nerve density (55, 148). Greaves et al.
reported that in response to estradiol, nerve fibers secreted
CCL2 and CSF-1, which attracted macrophages, which in turn
secreted neurotrophin 3 and brain-derived neurotrophin factor,
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stimulating neurogenesis (55). Recently a role for macrophage-
derived insulin-like growth factor-1 (IGF-1) as a key signal for
nerve outgrowth and sensitization in endometriosis has also
been described (54): depletion of peritoneal macrophages by
clodronate liposomes reversed abnormal pain behavior in mice
with induced endometriosis and notably reduced the number
of lesions in the peritoneal cavity, providing a direct link
between macrophages and endometriosis-associated pain/lesion
development. Macrophages treated with peritoneal fluid from
women with endometriosis exhibit an up regulation of IGF-1 at
the mRNA level, and mechanistically macrophage-derived IGF-
1 increased the growth of embryonic rat dorsal root ganglion
explants and this was reversed by an IGF-1 inhibitor. Similarly,
IGF-1 inhibition by the IGF-1 receptor inhibitor linsitinib in
a mouse model could reverse abnormal pain behaviors (54).
Taken together, macrophages are evidently pivotal to facilitating
neurogenesis and the generation endometriosis-associated pain
symptoms, and this is at least in part mediated by IGF-
1. The reciprocal signaling that occurs between macrophages
and nerve fibers therefore appears critical in regulating
neurogenesis in lesions and neuroinflammation is a key driver
of endometriosis pathophysiology.
Studies mechanistically indicate that macrophages play key
roles in growth, vascularization, and neurogenesis in lesions, as
well as generating pain in the condition and these experiments
have given insight into some of the factors expressed by
macrophages. However, the phenotype of macrophages in
endometriosis has not been fully characterized. Macrophages
in endometriosis lesions have long been described as being
wound healing and “M2-like,” however few studies have
taken into consideration the complexities of macrophage
phenotype, where pro-inflammatory and wound-healing like
markers often co-exist in response to complex signals from
the local tissue microenvironment (76). In humans, lesion
resident macrophages express the scavenger receptors CD163
and CD206, associated with hemoglobin scavenging and silent
clearance of debris (53). Cominelli et al. also identified CD163+
CD206+ macrophages in superficial lesions from women,
which also expressed high levels of matrix metalloproteinase-27,
associated with tissue remodeling (149). Duan et al. characterized
nitric oxide synthase (iNOS+) pro-inflammatory and CD163+
wound healing-like macrophages in mouse endometriosis lesions
(139). In a rhesus macaque model of endometriosis, lesions
were highly infiltrated by CD163+ macrophages (150). Whilst
macrophages in endometriosis lesions possessing a “wound
healing” like phenotype is synergistic with their role in
growth and angiogenesis in lesions, a more comprehensive
analysis of macrophage phenotype in endometriosis lesions
is required. It is also unknown whether different phenotypes
exist within endometriosis lesions, which could play differential
roles in pathology, and identifying these populations is
key for understanding which macrophage populations are
driving pathology.
Identification of endometrial macrophages and bone-marrow
monocyte-derived macrophages in endometriosis lesions
demonstrates that endometriosis-associated macrophages have
different origins, however differential roles for these populations
have not yet been investigated. It is possible that the endometrial
macrophages in lesions are monocyte-derived since a rapid
influx of classical monocytes into the endometrium is observed
during endometrial repair. Evidence of embryonically derived
tissue resident macrophages in lesions is yet to be demonstrated.
Previous studies have demonstrated that depletion of peritoneal
macrophages has pronounced effects on lesion size and
vascularization (53), depletion of this population translates to
reduced number of macrophages in lesions and attenuates pain
in mice (54). It remains unknown how endometrial and recruited
monocytes contribute to lesion establishment and maintenance.
Depletion of different macrophage populations prior to inducing
endometriosis in mice and at different time-points during the
life-course of the lesion will yield important insights into the
role of these pivotal cells in the disorder. Whilst macrophages
from 3 origins have been described the true heterogeneity of
macrophage phenotype in lesions and in the peritoneal fluid, in
endometriosis, is unknown. Application of single cell discovery
techniques and digital molecular pathology could provide vital
information on the complexities of endometriosis-associated
macrophage phenotype, and coupled with in vivo functional
studies identification of a disease-promoting population that
exhibits unique markers that differ from healthy macrophages
may be possible.
THE FUTURE: MACROPHAGE TARGETED
THERAPIES
Macrophages offer an attractive therapeutic target due to their
instrumental role in a number of pathologies (79). Inhibition
of macrophage signaling or recruitment, as well as re-education
of disease-associated macrophages to a “healthy” phenotype
could be of clinical benefit to patients where macrophages
are implicated in disease pathophysiology. Identification of
disease promoting macrophage populations and a detailed
understanding of their regulation, recruitment and phenotype is
a fundamental step before the development of therapeutics which
specifically target disease-associated macrophages is possible.
Due to the pivotal role that macrophages play in many cancers,
macrophage-targeted therapies have received much attention
in the literature and a number of in vivo studies and clinical
trials have demonstrated efficacy in using macrophage-mediated
treatments to improve clinical outcomes (79). A subset of
studies has targeted proliferation of TAMs in an effort to
alleviate tumor burden and improve clinical outcomes. Strachan
et al. demonstrated that targeting the Csf-1-receptor with
a small molecule inhibitor attenuated the turnover rate of
TAMs and decreased tumor growth in mouse models of breast
and cervical cancer (151). A phase I trial demonstrated a
significant reduction in macrophage number in solid tumors
after anti-Csf-1r treatment (152), and Csf-1r inhibition showed
an improvement in clinical outcomes including improvement
of symptoms in patients with diffuse-type giant cell tumors
(153). Inhibiting macrophage proliferation therefore appears
to be of clinical benefit in cancer models and subsets of
cancer patients. Future treatments should aim to specifically
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target disease-associated macrophage populations; Csf-1 is a
key regulator of macrophage proliferation and survival in most
tissues and neutralization or inhibition would affect healthy
macrophage populations and as such is not an ideal therapy
(154). The proliferative capacity of endometriosis lesion-resident
macrophages is currently unknown, thus further research is
required to determine whether this treatment strategy would be
of benefit to women with endometriosis.
Another potential mechanism of therapeutic intervention
could involve blocking recruitment of disease-promoting
macrophage populations. The CCL2/CCR2 recruitment
mechanism is implicated in a number of cancers and a CCR2
inhibitor to be administered alongside chemotherapy is
currently in phase 1b trials (155). Inhibition of recruitment
may be beneficial in blocking infiltration of macrophages into
endometriosis lesions, however the mechanisms, which regulate
recruitment into lesions, are currently poorly understood.
Whilst progression of research into macrophage-targeted
therapies is promising, current therapies do not specifically target
disease-promoting macrophages but have the potential to affect
macrophage populations throughout the whole body. However,
as our understanding of disease-modified macrophages
improves, it is evident that establishing macrophage origins
and phenotype heterogeneity in disease are crucial areas of
research before specific, targeted treatments can be designed
(72). Future work describing macrophage sub-populations,
active recruitment mechanisms and macrophage phenotype
in endometriosis is therefore critically required before
macrophage-targeted treatments may be a possibility for
women with endometriosis.
AUTHOR CONTRIBUTIONS
CH performed literature search and wrote manuscript. AH
provided feedback. EG conceptualized manuscript, provided
feedback, and wrote manuscript.
FUNDING
EG was funded by a Medical Research Council (MRC) Career
Development Award (MR/M009238/1). CH was supported
by an MRC Ph.D. studentship as part of an MRC Center
grant (MR/N022556/1).
ACKNOWLEDGMENTS
Thanks to Ronnie Grant for graphic design. Some figures were
generated using BioRender.com.
REFERENCES
1. Mahmood TA, Templeton A. Prevalence and genesis of endometriosis.Hum
Reprod. (1991) 6:544–9. doi: 10.1093/oxfordjournals.humrep.a137377
2. Johnson NP, Hummelshoj L, Adamson GD, Keckstein J, Taylor
HS, Abrao MS, et al. World Endometriosis Society consensus on
the classification of endometriosis. Hum Reprod. (2017) 32:315–24.
doi: 10.1093/humrep/dew293
3. Giudice LC. Clinical practice. Endometriosis.NEngl JMed. (2010) 362:2389–
98. doi: 10.1056/NEJMcp1000274
4. Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D,
D’Hooghe T. High prevalence of endometriosis in infertile women with
normal ovulation and normospermic partners. Fertil Steril. (2009) 92:68–74.
doi: 10.1016/j.fertnstert.2008.04.056
5. Hansen KA, Chalpe A, Eyster KM. Management of endometriosis-
associated pain. Clin Obstet Gynecol. (2010) 53:439–48.
doi: 10.1097/GRF.0b013e3181dbda06
6. Klein S, D’Hooghe T, Meuleman C, Dirksen C, Dunselman G, Simoens
S. What is the societal burden of endometriosis-associated symptoms?
a prospective Belgian study. Reprod Biomed Online. (2014) 28:116–24.
doi: 10.1016/j.rbmo.2013.09.020
7. Saraswat L, Ayansina DT, Cooper KG, Bhattacharya S, Miligkos D,
Horne AW, et al. Pregnancy outcomes in women with endometriosis:
a national record linkage study. BJOG. (2017) 124:444–52.
doi: 10.1111/1471-0528.13920
8. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes
I, et al. The burden of endometriosis: costs and quality of life of women
with endometriosis and treated in referral centres. Hum Reprod. (2012)
27:1292–9. doi: 10.1093/humrep/des073
9. Nnoaham KE, Hummelshoj L, Webster P, d’Hooghe T, de Cicco Nardone F,
de Cicco Nardone C, et al. Reprint of: impact of endometriosis on quality
of life and work productivity: a multicenter study across ten countries. Fertil
Steril. (2019) 112:e137–52. doi: 10.1016/j.fertnstert.2019.08.082
10. Bazot M, Darai E. Diagnosis of deep endometriosis: clinical examination,
ultrasonography, magnetic resonance imaging, and other techniques. Fertil
Steril. (2017) 108:886–94. doi: 10.1016/j.fertnstert.2017.10.026
11. Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the
medical treatment of endometriosis. Fertil Steril. (2017) 107:555–65.
doi: 10.1016/j.fertnstert.2016.12.025
12. Agarwal SK, FosterWG, Groessl EJ. Rethinking endometriosis care: applying
the chronic care model via a multidisciplinary program for the care
of women with endometriosis. Int J Womens Health. (2019) 11:405–10.
doi: 10.2147/IJWH.S207373
13. Vigano P, Candiani M, Monno A, Giacomini E, Vercellini P, Somigliana
E. Time to redefine endometriosis including its pro-fibrotic nature. Hum
Reprod. (2018) 33:347–52. doi: 10.1093/humrep/dex354
14. Laux-Biehlmann A, d’Hooghe T, Zollner TM. Menstruation pulls the trigger
for inflammation and pain in endometriosis. Trends Pharmacol Sci. (2015)
36:270–6. doi: 10.1016/j.tips.2015.03.004
15. Adamson GD. Endometriosis classification: an update. Curr Opin
Obstet Gynecol. (2011) 23:213–20. doi: 10.1097/GCO.0b013e328
348a3ba
16. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for
endometriosis and surgical menopause. Cochrane Database Syst Rev. (2009)
CD005997. doi: 10.1002/14651858.CD005997.pub2
17. Gallagher JS, Missmer SA, Hornstein MD, Laufer MR, Gordon CM, DiVasta
AD. Long-term effects of gonadotropin-releasing hormone agonists and
add-back in adolescent endometriosis. J Pediatr Adolesc Gynecol. (2018)
31:376–81. doi: 10.1016/j.jpag.2018.03.004
18. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De
Bie B, et al. ESHRE guideline: management of women with endometriosis.
Hum Reprod. (2014) 29:400–12. doi: 10.1093/humrep/det457
19. Malinak LR, Buttram VC Jr, Elias S, Simpson JL. Heritage aspects
of endometriosis. II. Clinical characteristics of familial endometriosis.
Am J Obstet Gynecol. (1980) 137:332–7. doi: 10.1016/0002-9378(80)
90918-7
20. Simpson JL, Elias S, Malinak LR, Buttram VC Jr. Heritable aspects of
endometriosis. I. Genetic studies. Am J Obstet Gynecol. (1980) 137:327–31.
doi: 10.1016/0002-9378(80)90917-5
21. Treloar SA, O’Connor DT, O’Connor VM,Martin NG. Genetic influences on
endometriosis in an Australian twin sample. sueT@qimr.edu.au. Fertil Steril.
(1999) 71:701–10. doi: 10.1016/S0015-0282(98)00540-8
Frontiers in Endocrinology | www.frontiersin.org 11 January 2020 | Volume 11 | Article 7
Hogg et al. Macrophages in Endometriosis
22. Nouri K, Ott J, Krupitz B, Huber JC, Wenzl R. Family incidence of
endometriosis in first-, second-, and third-degree relatives: case-control
study. Reprod Biol Endocrinol. (2010) 8:85. doi: 10.1186/1477-7827-8-85
23. Rahmioglu N, Nyholt DR, Morris AP, Missmer SA, Montgomery GW,
Zondervan KT. Genetic variants underlying risk of endometriosis:
insights from meta-analysis of eight genome-wide association
and replication datasets. Hum Reprod Update. (2014) 20:702–16.
doi: 10.1093/humupd/dmu015
24. Nyholt DR, Low SK, Anderson CA, Painter JN, Uno S, Morris AP, et al.
Genome-wide association meta-analysis identifies new endometriosis risk
loci. Nat Genet. (2012) 44:1355–9. doi: 10.1038/ng.2445
25. Sapkota Y, Steinthorsdottir V, Morris AP, Fassbender A, Rahmioglu N,
De Vivo I, et al. Meta-analysis identifies five novel loci associated with
endometriosis highlighting key genes involved in hormone metabolism. Nat
Commun. (2017) 8:15539. doi: 10.1038/ncomms15539
26. Nnoaham KE, Webster P, Kumbang J, Kennedy SH, Zondervan KT. Is
early age at menarche a risk factor for endometriosis? A systematic review
and meta-analysis of case-control studies. Fertil Steril. (2012) 98:702–12.e6.
doi: 10.1016/j.fertnstert.2012.05.035
27. Zeitoun K, Takayama K, Michael MD, Bulun SE. Stimulation of aromatase
P450 promoter (II) activity in endometriosis and its inhibition in
endometrium are regulated by competitive binding of steroidogenic
factor-1 and chicken ovalbumin upstream promoter transcription factor
to the same cis-acting element. Mol Endocrinol. (1999) 13:239–53.
doi: 10.1210/mend.13.2.0229
28. Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson
S, et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression
in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol
Metab. (1998) 83:4474–80. doi: 10.1210/jcem.83.12.5301
29. Osinski M, Wirstlein P, Wender-Ozegowska E, Mikolajczyk M, Jagodzinski
PP, Szczepanska M. HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR
expression in infertile women with endometriosis. Ginekol Pol. (2018)
89:125–34. doi: 10.5603/GP.a2018.0022
30. Yilmaz BD, Bulun SE. Endometriosis and nuclear receptors. Hum Reprod
Update. (2019) 25:473–85. doi: 10.1093/humupd/dmz005
31. Liang Y, Xie H,Wu J, Liu D, Yao S. Villainous role of estrogen inmacrophage-
nerve interaction in endometriosis. Reprod Biol Endocrinol. (2018) 16:122.
doi: 10.1186/s12958-018-0441-z
32. Rizner TL. Estrogen metabolism and action in endometriosis. Mol Cell
Endocrinol. (2009) 307:8–18. doi: 10.1016/j.mce.2009.03.022
33. Halme J, Becker S, Haskill S. Altered maturation and function of peritoneal
macrophages: possible role in pathogenesis of endometriosis. Am J Obstet
Gynecol. (1987) 156:783–9. doi: 10.1016/0002-9378(87)90333-4
34. Tariverdian N, Siedentopf F, Rucke M, Blois SM, Klapp BF, Kentenich
H, et al. Intraperitoneal immune cell status in infertile women with
and without endometriosis. J Reprod Immunol. (2009) 80:80–90.
doi: 10.1016/j.jri.2008.12.005
35. Oosterlynck DJ, Cornillie FJ, Waer M, Vandeputte M, Koninckx PR. Women
with endometriosis show a defect in natural killer activity resulting in
a decreased cytotoxicity to autologous endometrium. Fertil Steril. (1991)
56:45–51. doi: 10.1016/S0015-0282(16)54414-8
36. Jeung I, Cheon K, Kim MR. Decreased cytotoxicity of peripheral and
peritoneal natural killer cell in endometriosis. BioMed Res Int. (2016)
2016:2916070. doi: 10.1155/2016/2916070
37. Ho HN, Chao KH, Chen HF, Wu MY, Yang YS, Lee TY. Peritoneal
natural killer cytotoxicity and CD25+ CD3+ lymphocyte subpopulation are
decreased in women with stage III-IV endometriosis. Hum Reprod. (1995)
10:2671–5. doi: 10.1093/oxfordjournals.humrep.a135765
38. Wu MH, Shoji Y, Wu MC, Chuang PC, Lin CC, Huang MF, et al.
Suppression of matrix metalloproteinase-9 by prostaglandin E(2) in
peritoneal macrophage is associated with severity of endometriosis. Am J
Pathol. (2005) 167:1061–9. doi: 10.1016/S0002-9440(10)61195-9
39. Burney RO, Giudice LC. Pathogenesis and pathophysiology
of endometriosis. Fertil Steril. (2012) 98:511–9.
doi: 10.1016/j.fertnstert.2012.06.029
40. Gordts S, Koninckx P, Brosens I. Pathogenesis of deep endometriosis. Fertil
Steril. (2017) 108:872–85.e1. doi: 10.1016/j.fertnstert.2017.08.036
41. Sampson JA. Metastatic or embolic endometriosis, due to the menstrual
dissemination of endometrial tissue into the venous circulation. Am J Pathol.
(1927) 3:93–110.43.
42. Greaves E, Cousins FL, Murray A, Esnal-Zufiaurre A, Fassbender A,
Horne AW, et al. A novel mouse model of endometriosis mimics
human phenotype and reveals insights into the inflammatory
contribution of shed endometrium. Am J Pathol. (2014) 184:1930–9.
doi: 10.1016/j.ajpath.2014.03.011
43. Cousins FL, Kirkwood PM, Saunders PT, Gibson DA. Evidence for a
dynamic role for mononuclear phagocytes during endometrial repair and
remodelling. Sci Rep. (2016) 6:36748. doi: 10.1038/srep36748
44. Brosens I, Benagiano G. Is neonatal uterine bleeding involved in the
pathogenesis of endometriosis as a source of stem cells? Fertil Steril. (2013)
100:622–3. doi: 10.1016/j.fertnstert.2013.04.046
45. Troncon JK, Zani AC, Vieira AD, Poli-Neto OB, Nogueira AA, Rosa ESJC.
Endometriosis in a patient with mayer-rokitansky-kuster-hauser syndrome.
Case Rep Obstetr Gynecol. (2014) 2014:376231. doi: 10.1155/2014/376231
46. Jablonski C, Alifano M, Regnard JF, Gompel A. Pneumoperitoneum
associated with catamenial pneumothorax in women with
thoracic endometriosis. Fertil Steril. (2009) 91:930.e19–22.
doi: 10.1016/j.fertnstert.2008.09.071
47. Rousset-Jablonski C, Alifano M, Plu-Bureau G, Camilleri-Broet S, Rousset
P, Regnard JF, et al. Catamenial pneumothorax and endometriosis-related
pneumothorax: clinical features and risk factors. Hum Reprod. (2011)
26:2322–9. doi: 10.1093/humrep/der189
48. Martin JD Jr, Hauck AE. Endometriosis in the male.Am Surg. (1985) 51:426–
30.
49. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and
fibrosis. Immunity. (2016) 44:450–62. doi: 10.1016/j.immuni.2016.02.015
50. Abomaray F, Gidlof S, Gotherstrom C. Mesenchymal stromal cells are
more immunosuppressive in vitro if they are derived from endometriotic
lesions than from eutopic endometrium. StemCells Int. (2017) 2017:3215962.
doi: 10.1155/2017/3215962
51. Batt RE, Yeh J. Mullerianosis: four developmental (embryonic) mullerian
diseases. Reprod Sci. (2013) 20:1030–7. doi: 10.1177/1933719112472736
52. Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, et al.
Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate
from embryonic hematopoiesis and promote tumor progression. Immunity.
(2017) 47:597. doi: 10.1016/j.immuni.2017.08.018
53. Bacci M, Capobianco A, Monno A, Cottone L, Di Puppo F, Camisa B, et al.
Macrophages are alternatively activated in patients with endometriosis and
required for growth and vascularization of lesions in a mouse model of
disease. Am J Pathol. (2009) 175:547–56. doi: 10.2353/ajpath.2009.081011
54. Forster R, Sarginson A, Velichkova A, Hogg C, Dorning A, Horne AW,
et al. Macrophage-derived insulin-like growth factor-1 is a key neurotrophic
and nerve-sensitizing factor in pain associated with endometriosis. FASEB J.
(2019) 33:11210–22. doi: 10.1096/fj.201900797R
55. Greaves E, Temp J, Esnal-Zufiurre A, Mechsner S, Horne AW,
Saunders PT. Estradiol is a critical mediator of macrophage-nerve cross
talk in peritoneal endometriosis. Am J Pathol. (2015) 185:2286–97.
doi: 10.1016/j.ajpath.2015.04.012
56. Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases:
from pathogenesis to novel therapeutic strategies. Cell Mol Immunol. (2016)
13:316–27. doi: 10.1038/cmi.2015.104
57. Lloyd AF, Davies CL, Holloway RK, Labrak Y, Ireland G, Carradori
D, et al. Central nervous system regeneration is driven by microglia
necroptosis and repopulation. Nat Neurosci. (2019) 22:1046–52.
doi: 10.1038/s41593-019-0418-z
58. Lloyd AF, Miron VE. Cellular and molecular mechanisms underpinning
macrophage activation during remyelination. Front Cell Dev Biol. (2016)
4:60. doi: 10.3389/fcell.2016.00060
59. Bellido T. Osteocyte-driven bone remodeling.Calcif Tissue Int. (2014) 94:25–
34. doi: 10.1007/s00223-013-9774-y
60. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard
N, Kierdorf K, et al. A lineage of myeloid cells independent of
Myb and hematopoietic stem cells. Science. (2012) 336:86–90.
doi: 10.1126/science.1219179
Frontiers in Endocrinology | www.frontiersin.org 12 January 2020 | Volume 11 | Article 7
Hogg et al. Macrophages in Endometriosis
61. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al.
Tissue-resident macrophages self-maintain locally throughout adult life
with minimal contribution from circulating monocytes. Immunity. (2013)
38:792–804. doi: 10.1016/j.immuni.2013.04.004
62. Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L,
et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-
myeloid progenitors. Nature. (2015) 518:547–51. doi: 10.1038/nature13989
63. Hoeffel G, Chen J, Lavin Y, Low D, Almeida FF, See P, et al. C-
Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise
to adult tissue-resident macrophages. Immunity. (2015) 42:665–78.
doi: 10.1016/j.immuni.2015.03.011
64. Mass E, Ballesteros I, Farlik M, Halbritter F, Gunther P, Crozet L, et al.
Specification of tissue-resident macrophages during organogenesis. Science.
(2016) 353:aaf4238. doi: 10.1126/science.aaf4238
65. Ginhoux F, Jung S. Monocytes and macrophages: developmental
pathways and tissue homeostasis. Nat Rev Immunol. (2014) 14:392–404.
doi: 10.1038/nri3671
66. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K.
Development of monocytes, macrophages, and dendritic cells. Science.
(2010) 327:656–61. doi: 10.1126/science.1178331
67. Olingy CE, San Emeterio CL, Ogle ME, Krieger JR, Bruce AC, Pfau
DD, et al. Non-classical monocytes are biased progenitors of wound
healing macrophages during soft tissue injury. Sci Rep. (2017) 7:447.
doi: 10.1038/s41598-017-00477-1
68. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S,
et al. Monitoring of blood vessels and tissues by a population of
monocytes with patrolling behavior. Science. (2007) 317:666–70.
doi: 10.1126/science.1142883
69. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson
TE, et al. Minimal differentiation of classical monocytes as they survey
steady-state tissues and transport antigen to lymph nodes. Immunity. (2013)
39:599–610. doi: 10.1016/j.immuni.2013.08.007
70. Randolph GJ. The fate of monocytes in atherosclerosis. J Thromb Haemost.
(2009) 7 (Suppl. 1):28–30. doi: 10.1111/j.1538-7836.2009.03423.x
71. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M,
Hoffmann R, et al. Comparison of gene expression profiles between
human and mouse monocyte subsets. Blood. (2010) 115:e10–9.
doi: 10.1182/blood-2009-07-235028
72. Wynn TA, Chawla A, Pollard JW. Macrophage biology in
development, homeostasis and disease. Nature. (2013) 496:445–55.
doi: 10.1038/nature12034
73. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati
M. The chemokine system in diverse forms of macrophage
activation and polarization. Trends Immunol. (2004) 25:677–86.
doi: 10.1016/j.it.2004.09.015
74. Rey-Giraud F, Hafner M, Ries CH. In vitro generation of monocyte-derived
macrophages under serum-free conditions improves their tumor promoting
functions. PLoS ONE. (2012) 7:e42656. doi: 10.1371/journal.pone.0042656
75. Qian BZ, Pollard JW.Macrophage diversity enhances tumor progression and
metastasis. Cell. (2010) 141:39–51. doi: 10.1016/j.cell.2010.03.014
76. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage
activation: time for reassessment. F1000Prime Rep. (2014) 6:13.
doi: 10.12703/P6-13
77. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, et al. Gene-
expression profiles and transcriptional regulatory pathways that underlie the
identity and diversity of mouse tissue macrophages. Nat Immunol. (2012)
13:1118–28. doi: 10.1038/ni.2419
78. Johnson JL, Newby AC. Macrophage heterogeneity in
atherosclerotic plaques. Curr Opin Lipidol. (2009) 20:370–8.
doi: 10.1097/MOL.0b013e3283309848
79. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to
therapy. Immunity. (2014) 41:49–61. doi: 10.1016/j.immuni.2014.09.021
80. Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in
the context of rheumatoid arthritis. Nat Rev Rheumatol. (2016) 12:472–85.
doi: 10.1038/nrrheum.2016.91
81. Critchley HO, Kelly RW, Brenner RM, Baird DT. The endocrinology of
menstruation–a role for the immune system.Clin Endocrinol. (2001) 55:701–
10. doi: 10.1046/j.1365-2265.2001.01432.x
82. Arici A, MacDonald PC, Casey ML. Regulation of monocyte chemotactic
protein-1 gene expression in human endometrial cells in cultures. Mol Cell
Endocrinol. (1995) 107:189–97. doi: 10.1016/0303-7207(94)03442-V
83. Jones RL, Kelly RW, Critchley HO. Chemokine and cyclooxygenase-2
expression in human endometrium coincides with leukocyte accumulation.
Hum Reprod. (1997) 12:1300–6. doi: 10.1093/humrep/12.6.1300
84. Kitaya K, Nakayama T, Daikoku N, Fushiki S, Honjo H. Spatial and temporal
expression of ligands for CXCR3 and CXCR4 in human endometrium. J Clin
Endocrinol Metab. (2004) 89:2470–6. doi: 10.1210/jc.2003-031293
85. Eidukaite A, Tamosiunas V. Endometrial and peritoneal macrophages:
expression of activation and adhesion molecules. Am J Reprod Immunol.
(2004) 52:113–7. doi: 10.1111/j.1600-0897.2004.00201.x
86. Garry R, Hart R, Karthigasu KA, Burke C. Structural changes in
endometrial basal glands during menstruation. BJOG. (2010) 117:1175–85.
doi: 10.1111/j.1471-0528.2010.02630.x
87. Sharkey AM, Day K, McPherson A, Malik S, Licence D, Smith SK, et al.
Vascular endothelial growth factor expression in human endometrium
is regulated by hypoxia. J Clin Endocrinol Metab. (2000) 85:402–9.
doi: 10.1210/jc.85.1.402
88. Zhang X, Nothnick WB. The role and regulation of the uterine matrix
metalloproteinase system in menstruating and non-menstruating species.
Front Biosci. (2005) 10:353–66. doi: 10.2741/1533
89. Salamonsen LA, Zhang J, Brasted M. Leukocyte networks and human
endometrial remodelling. J Reprod Immunol. (2002) 57:95–108.
doi: 10.1016/S0165-0378(02)00011-6
90. Curry TE Jr, Osteen KG. The matrix metalloproteinase system: changes,
regulation, and impact throughout the ovarian and uterine reproductive
cycle. Endocr Rev. (2003) 24:428–65. doi: 10.1210/er.2002-0005
91. Jeziorska M, Nagase H, Salamonsen LA, Woolley DE. Immunolocalization
of the matrix metalloproteinases gelatinase B and stromelysin 1 in human
endometrium throughout the menstrual cycle. J Reprod Fertil. (1996)
107:43–51. doi: 10.1530/jrf.0.1070043
92. Pepe G, Braga D, Renzi TA, Villa A, Bolego C, D’Avila F, et al. Self-
renewal and phenotypic conversion are the main physiological responses
of macrophages to the endogenous estrogen surge. Sci Rep. (2017) 7:44270.
doi: 10.1038/srep44270
93. McLaren J, Prentice A, Charnock-Jones DS,Millican SA,Muller KH, Sharkey
AM, et al. Vascular endothelial growth factor is produced by peritoneal fluid
macrophages in endometriosis and is regulated by ovarian steroids. J Clin
Invest. (1996) 98:482–9. doi: 10.1172/JCI118815
94. Rochefort H, Chalbos D, Cunat S, Lucas A, Platet N, Garcia M.
Estrogen regulated proteases and antiproteases in ovarian and
breast cancer cells. J Steroid Biochem Mol Biol. (2001) 76:119–24.
doi: 10.1016/S0960-0760(00)00142-4
95. Stewart JA, Bulmer JN, Murdoch AP. Endometrial leucocytes:
expression of steroid hormone receptors. J Clin Pathol. (1998) 51:121–6.
doi: 10.1136/jcp.51.2.121
96. Cheng CW, Bielby H, Licence D, Smith SK, Print CG, Charnock-Jones DS.
Quantitative cellular and molecular analysis of the effect of progesterone
withdrawal in a murine model of decidualization. Biol Reprod. (2007)
76:871–83. doi: 10.1095/biolreprod.106.057950
97. Thiruchelvam U, Maybin JA, Armstrong GM, Greaves E, Saunders PT,
Critchley HO. Cortisol regulates the paracrine action of macrophages by
inducing vasoactive gene expression in endometrial cells. J Leukoc Biol.
(2016) 99:1165–71. doi: 10.1189/jlb.5A0215-061RR
98. Ghosn EE, Cassado AA, Govoni GR, Fukuhara T, Yang Y, Monack
DM, et al. Two physically, functionally, and developmentally distinct
peritoneal macrophage subsets. Proc Natl Acad Sci USA. (2010) 107:2568–73.
doi: 10.1073/pnas.0915000107
99. Jackson-Jones LH, Benezech C. Control of innate-like B cell location for
compartmentalised IgM production. Curr Opin Immunol. (2018) 50:9–13.
doi: 10.1016/j.coi.2017.10.006
100. Rosas M, Davies LC, Giles PJ, Liao CT, Kharfan B, Stone TC,
et al. The transcription factor Gata6 links tissue macrophage
phenotype and proliferative renewal. Science. (2014) 344:645–8.
doi: 10.1126/science.1251414
101. Bain CC, Hawley CA, Garner H, Scott CL, Schridde A, Steers NJ,
et al. Long-lived self-renewing bone marrow-derived macrophages displace
Frontiers in Endocrinology | www.frontiersin.org 13 January 2020 | Volume 11 | Article 7
Hogg et al. Macrophages in Endometriosis
embryo-derived cells to inhabit adult serous cavities. Nat Commun. (2016)
7:ncomms11852. doi: 10.1038/ncomms11852
102. Cassado Ados A, D’Imperio Lima MR, Bortoluci KR. Revisiting mouse
peritoneal macrophages: heterogeneity, development, and function. Front
Immunol. (2015) 6:225. doi: 10.3389/fimmu.2015.00225
103. Kubicka U, Olszewski WL, Tarnowski W, Bielecki K, Ziolkowska A,
Wierzbicki Z. Normal human immune peritoneal cells: subpopulations
and functional characteristics. Scand J Immunol. (1996) 44:157–63.
doi: 10.1046/j.1365-3083.1996.d01-297.x
104. Irvine KM, Banh X, Gadd VL, Wojcik KK, Ariffin JK, Jose S, et al.
CRIg-expressing peritoneal macrophages are associated with disease severity
in patients with cirrhosis and ascites. JCI Insight. (2016) 1:e86914.
doi: 10.1172/jci.insight.86914
105. Barth MW, Hendrzak JA, Melnicoff MJ, Morahan PS. Review of the
macrophage disappearance reaction. J Leukoc Biol. (1995) 57:361–7.
doi: 10.1002/jlb.57.3.361
106. Okabe Y, Medzhitov R. Tissue-specific signals control reversible program
of localization and functional polarization of macrophages. Cell. (2014)
157:832–44. doi: 10.1016/j.cell.2014.04.016
107. Davies LC, Rosas M, Smith PJ, Fraser DJ, Jones SA, Taylor PR. A quantifiable
proliferative burst of tissue macrophages restores homeostatic macrophage
populations after acute inflammation. Eur J Immunol. (2011) 41:2155–64.
doi: 10.1002/eji.201141817
108. Gautier EL, Ivanov S, Lesnik P, Randolph GJ. Local apoptosis mediates
clearance of macrophages from resolving inflammation in mice. Blood.
(2013) 122:2714–22. doi: 10.1182/blood-2013-01-478206
109. Liao CT, Rosas M, Davies LC, Giles PJ, Tyrrell VJ, O’Donnell VB, et al.
IL-10 differentially controls the infiltration of inflammatory macrophages
and antigen-presenting cells during inflammation. Eur J Immunol. (2016)
46:2222–32. doi: 10.1002/eji.201646528
110. Wong K, Valdez PA, Tan C, Yeh S, Hongo JA, OuyangW. Phosphatidylserine
receptor Tim-4 is essential for the maintenance of the homeostatic state of
resident peritoneal macrophages. Proc Natl Acad Sci USA. (2010) 107:8712–
7. doi: 10.1073/pnas.0910929107
111. Wang J, Kubes P. A reservoir of mature cavity macrophages that can
rapidly invade visceral organs to affect tissue repair. Cell. (2016) 165:668–78.
doi: 10.1016/j.cell.2016.03.009
112. Ruckerl D, Campbell SM, Duncan S, Sutherland TE, Jenkins SJ,
Hewitson JP, et al. Macrophage origin limits functional plasticity
in helminth-bacterial co-infection. PLoS Pathog. (2017) 13:e1006233.
doi: 10.1371/journal.ppat.1006233
113. Cassado Ados A, de Albuquerque JA, Sardinha LR, Buzzo Cde L, Faustino L,
Nascimento R, et al. Cellular renewal and improvement of local cell effector
activity in peritoneal cavity in response to infectious stimuli. PLoS ONE.
(2011) 6:e22141. doi: 10.1371/journal.pone.0022141
114. Bellingan GJ, Caldwell H, Howie SE, Dransfield I, Haslett C. In vivo fate
of the inflammatory macrophage during the resolution of inflammation:
inflammatory macrophages do not die locally, but emigrate to the draining
lymph nodes. J Immunol. (1996) 157:2577–85.
115. Yona S, Kim KW,Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping
reveals origins and dynamics of monocytes and tissue macrophages under
homeostasis. Immunity. (2013) 38:79–91. doi: 10.1016/j.immuni.2013.05.008
116. Bain CC, Jenkins SJ. The biology of serous cavity macrophages. Cell
Immunol. (2018) 330:126–35. doi: 10.1016/j.cellimm.2018.01.003
117. Burnett SH, Beus BJ, Avdiushko R, Qualls J, Kaplan AM, Cohen DA.
Development of peritoneal adhesions in macrophage depleted mice. J Surg
Res. (2006) 131:296–301. doi: 10.1016/j.jss.2005.08.026
118. Wang Y, Nicholes K, Shih IM. The origin and pathogenesis of endometriosis.
Annu Rev Pathol. (2019). doi: 10.1146/annurev-pathmechdis-012419-032654
119. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, et al.
Prognostic significance of tumor-associated macrophages in solid
tumor: a meta-analysis of the literature. PLoS ONE. (2012) 7:e50946.
doi: 10.1371/journal.pone.0050946
120. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol.
(2013) 33 (Suppl. 1):S79–84. doi: 10.1007/s10875-012-9847-0
121. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2
recruits inflammatory monocytes to facilitate breast-tumour metastasis.
Nature. (2011) 475:222–5. doi: 10.1038/nature10138
122. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe
J, et al. Chemokine-mediated rapid turnover of myeloid-derived
suppressor cells in tumor-bearing mice. Blood. (2008) 111:5457–66.
doi: 10.1182/blood-2008-01-136895
123. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A,
Berger C, et al. Origins of tumor-associated macrophages and neutrophils.
Proc Natl Acad Sci USA. (2012) 109:2491–6. doi: 10.1073/pnas.1113
744109
124. Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y, et al. Estrogen represses
hepatocellular carcinoma (HCC) growth via inhibiting alternative activation
of tumor-associated macrophages (TAMs). J Biol Chem. (2012) 287:40140–9.
doi: 10.1074/jbc.M112.348763
125. Sekiguchi K, Ito Y, Hattori K, Inoue T, Hosono K, Honda M, et al.
VEGF receptor 1-expressing macrophages recruited from bone marrow
enhances angiogenesis in endometrial tissues. Sci Rep. (2019) 9:7037.
doi: 10.1038/s41598-019-43185-8
126. Hey YY, Tan JK, O’Neill HC. Redefining myeloid cell subsets in murine
spleen. Front Immunol. (2015) 6:652. doi: 10.3389/fimmu.2015.00652
127. Capobianco A, Monno A, Cottone L, Venneri MA, Biziato D, Di Puppo
F, et al. Proangiogenic Tie2(+) macrophages infiltrate human and murine
endometriotic lesions and dictate their growth in a mouse model of the
disease. Am J Pathol. (2011) 179:2651–9. doi: 10.1016/j.ajpath.2011.07.029
128. Berbic M, Schulke L, Markham R, Tokushige N, Russell P, Fraser IS.
Macrophage expression in endometrium of women with and without
endometriosis. Hum Reprod. (2009) 24:325–32. doi: 10.1093/humrep/
den393
129. Takebayashi A, Kimura F, Kishi Y, Ishida M, Takahashi A, Yamanaka
A, et al. Subpopulations of macrophages within eutopic endometrium
of endometriosis patients. Am J Reprod Immunol. (2015) 73:221–31.
doi: 10.1111/aji.12331
130. Jolicoeur C, Boutouil M, Drouin R, Paradis I, Lemay A, Akoum A. Increased
expression of monocyte chemotactic protein-1 in the endometrium of
women with endometriosis. Am J Pathol. (1998) 152:125–33.
131. Collette T, Maheux R, Mailloux J, Akoum A. Increased expression
of matrix metalloproteinase-9 in the eutopic endometrial tissue
of women with endometriosis. Hum Reprod. (2006) 21:3059–67.
doi: 10.1093/humrep/del297
132. Yang HL, Zhou WJ, Chang KK, Mei J, Huang LQ, Wang MY, et al.
The crosstalk between endometrial stromal cells and macrophages impairs
cytotoxicity of NK cells in endometriosis by secreting IL-10 and TGF-beta.
Reproduction. (2017) 154:815–25. doi: 10.1530/REP-17-0342
133. Beste MT, Pfaﬄe-Doyle N, Prentice EA, Morris SN, Lauffenburger DA,
Isaacson KB, et al. Molecular network analysis of endometriosis reveals a role
for c-Jun-regulatedmacrophage activation. Sci TranslMed. (2014) 6:222ra16.
doi: 10.1126/scitranslmed.3007988
134. Fan YY, Chen HY, Chen W, Liu YN, Fu Y, Wang LN. Expression of
inflammatory cytokines in serum and peritoneal fluid from patients with
different stages of endometriosis. Gynecol Endocrinol. (2018) 34:507–12.
doi: 10.1080/09513590.2017.1409717
135. Yuan M, Li D, An M, Li Q, Zhang L, Wang G. Rediscovering peritoneal
macrophages in a murine endometriosis model. Hum Reprod. (2017) 32:94–
102. doi: 10.1093/humrep/dew274
136. Johan MZ, Ingman WV, Robertson SA, Hull ML. Macrophages infiltrating
endometriosis-like lesions exhibit progressive phenotype changes in
a heterologous mouse model. J Reprod Immunol. (2019) 132:1–8.
doi: 10.1016/j.jri.2019.01.002
137. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages:
mechanism of action, preparation of liposomes and applications. J Immunol
Methods. (1994) 174:83–93. doi: 10.1016/0022-1759(94)90012-4
138. Haber E, Danenberg HD, Koroukhov N, Ron-El R, Golomb G, Schachter M.
Peritoneal macrophage depletion by liposomal bisphosphonate attenuates
endometriosis in the rat model. Hum Reprod. (2009) 24:398–407.
doi: 10.1093/humrep/den375
139. Duan J, Liu X, Wang H, Guo SW. The M2a macrophage subset may be
critically involved in the fibrogenesis of endometriosis in mice. Reprod
Biomed Online. (2018) 37:254–68. doi: 10.1016/j.rbmo.2018.05.017
140. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage
subsets. Nat Rev Immunol. (2011) 11:723–37. doi: 10.1038/nri3073
Frontiers in Endocrinology | www.frontiersin.org 14 January 2020 | Volume 11 | Article 7
Hogg et al. Macrophages in Endometriosis
141. Chan RWS, Lee C-L, Ng EHY, Yeung WSB. Co-culture with macrophages
enhances the clonogenic and invasion activity of endometriotic stromal cells.
Cell Prolif. (2017) 50:e12330. doi: 10.1111/cpr.12330
142. Mei J, Chang KK, Sun HX. Immunosuppressive macrophages induced by
IDO1 promote the growth of endometrial stromal cells in endometriosis.Mol
Med Rep. (2017) 15:2255–60. doi: 10.3892/mmr.2017.6242
143. Shao J, Zhang B, Yu JJ, Wei CY, Zhou WJ, Chang KK, et al. Macrophages
promote the growth and invasion of endometrial stromal cells by
downregulating IL-24 in endometriosis. Reproduction. (2016) 152:673–82.
doi: 10.1530/REP-16-0278
144. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic
translation for fibrotic disease. Nat Med. (2012) 18:1028–40. doi: 10.1038/
nm.2807
145. McKinnon B, Bersinger NA, Wotzkow C, Mueller MD. Endometriosis-
associated nerve fibers, peritoneal fluid cytokine concentrations, and pain in
endometriotic lesions from different locations. Fertil Steril. (2012) 97:373–80.
doi: 10.1016/j.fertnstert.2011.11.011
146. Tokushige N, Markham R, Russell P, Fraser IS. Nerve fibres in peritoneal
endometriosis. Hum Reprod. (2006) 21:3001–7. doi: 10.1093/humrep/del260
147. Arnold J, Barcena de Arellano ML, Ruster C, Vercellino GF, Chiantera
V, Schneider A, et al. Imbalance between sympathetic and sensory
innervation in peritoneal endometriosis. Brain Behav Immun. (2012) 26:132–
41. doi: 10.1016/j.bbi.2011.08.004
148. Tran LV, Tokushige N, Berbic M, Markham R, Fraser IS. Macrophages and
nerve fibres in peritoneal endometriosis. Hum Reprod. (2009) 24:835–41.
doi: 10.1093/humrep/den483
149. Cominelli A, Gaide Chevronnay HP, Lemoine P, Courtoy PJ, Marbaix E,
Henriet P. Matrix metalloproteinase-27 is expressed in CD163+/CD206+
M2 macrophages in the cycling human endometrium and in
superficial endometriotic lesions. Mol Hum Reprod. (2014) 20:767–75.
doi: 10.1093/molehr/gau034
150. Smith KA, Pearson CB, Hachey AM, Xia DL, Wachtman LM. Alternative
activation of macrophages in rhesus macaques (Macaca mulatta) with
endometriosis. Comp Med. (2012) 62:303–10.
151. Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, et al.
CSF1R inhibition delays cervical and mammary tumor growth in murine
models by attenuating the turnover of tumor-associated macrophages and
enhancing infiltration by CD8(+) T cells.Oncoimmunology. (2013) 2:e26968.
doi: 10.4161/onci.26968
152. Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde
M, D’Angelo SP, et al. Phase I study of emactuzumab single agent or
in combination with paclitaxel in patients with advanced/metastatic solid
tumors reveals depletion of immunosuppressive M2-like macrophages. Ann
Oncol. (2019) 30:1381–92. doi: 10.1093/annonc/mdz163
153. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V,
et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody
reveals a strategy for cancer therapy. Cancer Cell. (2014) 25:846–59.
doi: 10.1016/j.ccr.2014.05.016
154. Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring
Harb Perspect Biol. (2014) 6:a021857. doi: 10.1101/cshperspect.a021857
155. Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth
BM, et al. Targeting tumour-associated macrophages with CCR2 inhibition
in combination with FOLFIRINOX in patients with borderline resectable
and locally advanced pancreatic cancer: a single-centre, open-label, dose-
finding, non-randomised, phase 1b trial. Lancet Oncol. (2016) 17:651–62.
doi: 10.1016/S1470-2045(16)00078-4
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Hogg, Horne and Greaves. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Endocrinology | www.frontiersin.org 15 January 2020 | Volume 11 | Article 7
